Unknown PHASE4 INTERVENTIONAL 2-arm NCT01341353

Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

Atrial Fibrillation Therapy: A Multi-Center Clinical Study

Sponsor: Capital Medical University

Interventions Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists catheter ablation

Updated 6 times since 2017 Last updated: Apr 21, 2011 Started: Apr 30, 2011 Primary completion: Dec 31, 2014 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01341353, this PHASE4 trial focuses on Atrial Fibrillation and remains ongoing. Sponsored by Capital Medical University, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Dec 2019 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Dec 2019 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Capital Medical University
Dalian Medical University
Guangdong Provincial People's Hospital
Nanjing Medical University
Peking Union Medical College
Shanghai Chest Hospital
West China Hospital
Wuhan University

Data source: Wuhan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China